| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial RS Bresalier, RS Sandler, H Quan, JA Bolognese, B Oxenius, K Horgan, ... New England Journal of Medicine 352 (11), 1092-1102, 2005 | 3315 | 2005 |
| Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis UA Liberman, SR Weiss, J Bröll, HW Minne, H Quan, NH Bell, ... New England Journal of Medicine 333 (22), 1437-1444, 1995 | 2983 | 1995 |
| Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs MJ Langman, DM Jensen, DJ Watson, SE Harper, PL Zhao, H Quan, ... Jama 282 (20), 1929-1933, 1999 | 895 | 1999 |
| Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids F Catella-Lawson, B McAdam, BW Morrison, S Kapoor, D Kujubu, L Antes, ... Journal of Pharmacology and Experimental Therapeutics 289 (2), 735-741, 1999 | 808 | 1999 |
| A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis L Laine, S Harper, T Simon, R Bath, J Johanson, H Schwartz, S Stern, ... Gastroenterology 117 (4), 776-783, 1999 | 631 | 1999 |
| A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas JA Baron, RS Sandler, RS Bresalier, H Quan, R Riddell, A Lanas, ... Gastroenterology 131 (6), 1674-1682, 2006 | 566 | 2006 |
| Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial SK Swan, DW Rudy, KC Lasseter, CF Ryan, KL Buechel, LJ Lambrecht, ... Annals of internal medicine 133 (1), 1-9, 2000 | 479 | 2000 |
| Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double … C Hawkey, L Laine, T Simon, A Beaulieu, J Maldonado‐Cocco, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2000 | 448 | 2000 |
| Studies of the oral bioavailability of alendronate BJ Gertz, SD Holland, WF Kline, BK Matuszewski, A Freeman, H Quan, ... Clinical Pharmacology & Therapeutics 58 (3), 288-298, 1995 | 330 | 1995 |
| Monitoring bone resorption in early postmenopausal women by an immunoassay for cross‐linked collagen peptides in urine BJ Gertz, P Shao, DA Hanson, H Quan, ST Harris, HK Genant, ... Journal of Bone and Mineral Research 9 (2), 135-142, 1994 | 262 | 1994 |
| Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial L Laine, ES Maller, C Yu, H Quan, T Simon Gastroenterology 127 (2), 395-402, 2004 | 260 | 2004 |
| The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events RH Hunt, S Harper, DJ Watson, C Yu, H Quan, M Lee, JK Evans, ... Official journal of the American College of Gastroenterology| ACG 98 (8 …, 2003 | 251 | 2003 |
| Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen FL Lanza, MF Rack, TJ Simon, H Quan, JA Bolognese, ME Hoover, ... Alimentary pharmacology & therapeutics 13 (6), 761-767, 1999 | 220 | 1999 |
| Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis DJ Watson, SE Harper, PL Zhao, H Quan, JA Bolognese, TJ Simon Archives of Internal Medicine 160 (19), 2998-3003, 2000 | 214 | 2000 |
| Some statistical methods for multiple endpoints in clinical trials J Zhang, H Quan, J Ng, ME Stepanavage Controlled clinical trials 18 (3), 204-221, 1997 | 197 | 1997 |
| Assessing reproducibility by the within-subject coefficient of variation with random effects models H Quan, WJ Shih Biometrics, 1195-1203, 1996 | 171 | 1996 |
| COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin G Sigthorsson, R Crane, T Simon, M Hoover, H Quan, J Bolognese, ... Gut 47 (4), 527-532, 2000 | 160 | 2000 |
| Complementary studies of the gastrointestinal safety of the cyclo‐oxygenase‐2‐selective inhibitor etoricoxib RH Hunt, S Harper, P Callegari, C Yu, H Quan, J Evans, C James, ... Alimentary pharmacology & therapeutics 17 (2), 201-210, 2003 | 141 | 2003 |
| Sample size considerations for Japanese patients in a multi‐regional trial based on MHLW guidance H Quan, PL Zhao, J Zhang, M Roessner, K Aizawa Pharmaceutical Statistics 9 (2), 100-112, 2010 | 117 | 2010 |
| The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study F Lanza, B Sahba, H Schwartz, S Winograd, J Torosis, H Quan, R Reyes, ... Official journal of the American College of Gastroenterology| ACG 97 (1), 58-64, 2002 | 110 | 2002 |
